Background: Medulloblastoma (MB) is the most common malignant paediatric brain tumor. Among distinct MB subtypes, Group 3 represents one of the most aggressive subtypes, with high relapse rate, frequent metastasis, and mortality. These malignant traits are largely driven by MB stem cells (MBSCs), a subpopulation with enhanced self-renewal capacity and resistance to standard therapies, making them prime targets for innovative treatment strategies. Methods: Group 3 MB human cell lines were treated with 0.3 µM Brefeldin A (BFA), a potent inducer of endoplasmic reticulum stress. Proteomic analyses via nano-LC-MS/MS were employed to investigate structural alterations in CD133, a key cell surface and stemness-associated receptor. Finally, computational screening was performed to identify Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved compounds, with improved pharmacokinetic and pharmacodynamic profiles that mimic BFA’s mechanism of action. Results: We demonstrate that BFA induced structural disruption of CD133 and compromised MBSCs stem-like phenotype. This loss of stem-like properties correlates with diminished clonogenic potential, downregulation of the oncogenic PI3K/AKT/mTOR signaling axis, and impaired intercellular communication. Importantly, we identified clinically approved compounds capable of recapitulating the biological effects associated with BFA treatment. Conclusions: This study uncovers a previously unrecognized mechanism of CD133 structural modulation and highlights the existence of clinically approved compounds that may impair MBSC function, offering a promising possible avenue for targeting therapy-resistant tumor-initiating cells in aggressive Group 3 MB.

CD133 structural instability as a gateway to medulloblastoma vulnerability / Spinello, Z., Brunetti, M., Pediconi, N., Trocchianesi, S., Giusti, L., Abballe, L., Masuelli, L., Bei, R., Miele, E., Po, A., Citarella, A., Ruggiero, G., Di Cintio, F., Ragusa, A., Mastronuzzi, A., Locatelli, F., Ferretti, E., Ronci, M., Catanzaro, G.. - In: CANCER CELL INTERNATIONAL. - ISSN 1475-2867. - 26:1(2026). [10.1186/s12935-026-04398-w]

CD133 structural instability as a gateway to medulloblastoma vulnerability

Brunetti, Martina;Pediconi, Natalia;Trocchianesi, Sofia;Abballe, Luana;Masuelli, Laura;Po, Agnese;Citarella, Anna;Ruggiero, Giacomo;Mastronuzzi, Angela;Ferretti, Elisabetta;
2026

Abstract

Background: Medulloblastoma (MB) is the most common malignant paediatric brain tumor. Among distinct MB subtypes, Group 3 represents one of the most aggressive subtypes, with high relapse rate, frequent metastasis, and mortality. These malignant traits are largely driven by MB stem cells (MBSCs), a subpopulation with enhanced self-renewal capacity and resistance to standard therapies, making them prime targets for innovative treatment strategies. Methods: Group 3 MB human cell lines were treated with 0.3 µM Brefeldin A (BFA), a potent inducer of endoplasmic reticulum stress. Proteomic analyses via nano-LC-MS/MS were employed to investigate structural alterations in CD133, a key cell surface and stemness-associated receptor. Finally, computational screening was performed to identify Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved compounds, with improved pharmacokinetic and pharmacodynamic profiles that mimic BFA’s mechanism of action. Results: We demonstrate that BFA induced structural disruption of CD133 and compromised MBSCs stem-like phenotype. This loss of stem-like properties correlates with diminished clonogenic potential, downregulation of the oncogenic PI3K/AKT/mTOR signaling axis, and impaired intercellular communication. Importantly, we identified clinically approved compounds capable of recapitulating the biological effects associated with BFA treatment. Conclusions: This study uncovers a previously unrecognized mechanism of CD133 structural modulation and highlights the existence of clinically approved compounds that may impair MBSC function, offering a promising possible avenue for targeting therapy-resistant tumor-initiating cells in aggressive Group 3 MB.
2026
CD133; Drug discovery; Medulloblastoma; Medulloblastoma stem cells; Nano-LC-MS/MS
01 Pubblicazione su rivista::01a Articolo in rivista
CD133 structural instability as a gateway to medulloblastoma vulnerability / Spinello, Z., Brunetti, M., Pediconi, N., Trocchianesi, S., Giusti, L., Abballe, L., Masuelli, L., Bei, R., Miele, E., Po, A., Citarella, A., Ruggiero, G., Di Cintio, F., Ragusa, A., Mastronuzzi, A., Locatelli, F., Ferretti, E., Ronci, M., Catanzaro, G.. - In: CANCER CELL INTERNATIONAL. - ISSN 1475-2867. - 26:1(2026). [10.1186/s12935-026-04398-w]
File allegati a questo prodotto
File Dimensione Formato  
12935_2026_Article_4398.pdf

accesso aperto

Note: Spinello_CD133_2026
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 5.38 MB
Formato Adobe PDF
5.38 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1781360
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact